Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LongeVC is a venture capital firm located in Washington D.C. that specializes in biotechnology and longevity investments. The firm manages a portfolio of 25 companies and focuses on early-stage funding, including pre-seed, seed, seed-plus, and Series A rounds. Their mission is to support founders in bringing groundbreaking biotech solutions to market.
LongeVC invests in early-stage companies developing solutions in personalized medicine, advanced diagnostics, and foundational platform technologies. Their investment strategy targets pre-clinical and clinical stage drug development that investigates the molecular and cellular mechanisms of aging. Typical investments are made in companies that facilitate faster drug discovery and testing.
Notable companies in LongeVC's portfolio include Trogenix, which develops precision cancer treatments; Stealth Company, focusing on in vivo biofactories; and CatenaBio, known for creating novel therapeutics. Other portfolio companies include Constructive Bio, Turn.bio, ProtonIntel, and Rubedo Life Sciences.
Submit your pitch through their form at longevc.com or email your deck to hq@longevc.com.
Yes, LongeVC often leads investment rounds in the companies they back, particularly in early-stage funding.
LongeVC is open to follow-on investments, especially if the company continues to align with their focus on biotechnology and longevity.
Specific details about the size of LongeVC's current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.